Drug class in one race
GPRC5D x CD3 drugs for Multiple Myeloma
5 tracked GPRC5D x CD3 drugs in the Multiple Myeloma race. The class explanation lives on the GPRC5D x CD3 page; the full indication pipeline across every mechanism is on the Multiple Myeloma page.
1 approved / phase 41 Phase 32 Phase 1/21 Phase 1
Head-to-head evidence: Forimtamig vs LBL-034 · Forimtamig vs QLS32015 · Forimtamig vs TQB2029 · Forimtamig vs Talquetamab